Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erenumab in chronic migraine (Asian population)
NCT03867201Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2019
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in chronic migraine comparing Erenumab with Placebo (2 arms). Primary endpoint: Monthly Migraine Days at 12 weeks. Started Aug 2019; status: completed.
02
Drugs
erenumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT03867201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03867201.